J Korean Med Assoc.  2019 Apr;62(4):182-185. 10.5124/jkma.2019.62.4.182.

Issues on carcinogen contaminated antihypertensive drugs and constructing drug safety management system

• Park BJ

• KMID: 2442732
• DOI: http://doi.org/10.5124/jkma.2019.62.4.182

Abstract

European Medicines Agency withdrew valsartan from European market in July 2018 because it was contaminated with carcinogen, N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA). Medicines and Healthcare Products Regulatory Agency also found the same contamination and withdrew it from England market. US Food and Drug Administration followed the action after confirming its contamination. Ministry of Food and Drug Safety (MFDS) conducted testing all the valsartans at Korean market and withdrew some of them from market after confirming the contamination with NDMA. MFDS provided the pharmaceutical companies and laboratory institutions with the manual for testing both NDMA and NDEA and educated relevant personnels. MFDS also evaluated the health impact of the contaminated valsartan on the hypertensive patients who took the valsartan, which was shown to be very low risk of additional cancer incidence. MFDS pronounced strengthening of the safety management for the raw materials of the medicines. For guaranteeing the safety of medicines, more comprehensive drug safety management system from developing new drugs to consuming the medicines should be established. For achieving such a goal, active participation of all the stakeholders of the medicines including governmental agencies including MFDS and Ministry of Health and Welfare, the National Assembly, healthcare professionals, pharmaceutical companies, mass media, and general population including patients should be needed.

Keyword

Antihypertensive agents; Valsartan; Dimethylnitrosamine; Diethylnitrosamine; Drug safety

MeSH Terms

Antihypertensive Agents*
Delivery of Health Care
Diethylnitrosamine
Dimethylnitrosamine
England
Humans
Incidence
Mass Media
Safety Management*
United States Food and Drug Administration
Valsartan
Antihypertensive Agents
Diethylnitrosamine
Dimethylnitrosamine
Valsartan

Reference

1. European Medicines Agency. EU authorities take further action in ongoing review of sartans: Zheijiang Huahai placed under increased supervision; Aurobindo Pharma stopped from supplying irbesartan to the EU [Internet]. London: European Medicines Agency;2018. cited 2019 Mar 2. Available from: https://www.ema.europa.eu/en/documents/press-release/eu-authorities-take-further-action-ongoing-review-sartans_en.pdf.

2. Medicines and Healthcare Products Regulatory Agency. Additional blood pressure and heart medication recalled from pharmacies [Internet]. London: Medicines and Healthcare Products Regulatory Agency;2019. cited 2019 Mar 2. Available from: https://www.gov.uk/government/news/additional-blood-pressure-and-heart-medication-recalled-from-pharmacies.-heart-medication-recalled-from-pharmacies.

3. US Food and Drug Administration. Drug recalls [Internet]. Silver Spring: US Food and Drug Administration;2019. cited 2019 Mar 2. Available from: https://www.fda.gov/Drugs/DrugSafety/DrugRecalls/default.htm.

4. Ministry of Food and Drug Safety. MFDS completed investigating all the valsartans (raw material for antihypertensive drug) 23/08/2018 [Internet]. Cheongju: Ministry of Food and Drug Safety;2018. cited 2019 Mar 1. Available from: http://www.mfds.go.kr/brd/m_99/view.do?seq=42992.

5. Ministry of Food and Drug Safety. MFDS distributed a guideline for managing sartan's impurity 21/11/2018 [Internet]. Cheongju: Ministry of Food and Drug Safety;2018. cited 2019 Mar 1. Available from: http://www.mfds.go.kr/brd/m_99/view.do?seq=43128.

6. Ministry of Food and Drug Safety. MFDS reported the results of evaluating the clinical outcome of patients taking valsartan (raw material for antihypertensive drug) and further investigation19/12/2018 [Internet]. Cheongju: Ministry of Food and Drug Safety;2018. cited 2019 Mar 1. Available from: http://www.mfds.go.kr/brd/m_99/view.do?seq=43167.

7. Ministry of Food and Drug Safety. Korea became a regular member of ICH, which proved Korea to be an advanced country in drug regulation14/11/2016 [Internet]. Cheongju: Ministry of Food and Drug Safety;cited 2019 Mar 1. Available from: http://www.mfds.go.kr/brd/m_99/view.do?seq=34354.

8. Park BJ. Role of pharmaceutical companies in pharmacoepidemiology and risk management. In : Park BJ, editor. Pharmacoepidemiology. Seoul: Seoul National University Press;2011. p. 49–58.

9. Park BJ. Role of clinicians in pharmacoepidemiology and risk management. In : Park BJ, editor. Pharmacoepidemiology. Seoul: Seoul National University Press;2011. p. 30–39.

10. Park BJ. Cohort study. In : Park BJ, editor. Pharmacoepidemiology. Seoul: Seoul National University Press;2011. p. 192–203.

11. Park BJ. Role of government in pharmacoepidemiology and risk management. In : Park BJ, editor. Pharmacoepidemiology. Seoul: Seoul National University Press;2011. p. 59–71.